Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 4/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ATIC | P31939 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 2/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorsulfaquinoxaline SCHEMBL29557567 | 1.00 | LMNA (0.68) | LMNACYP2C9SMN1; SMN2KDM4ENPSR1 | |
| SCHEMBL23773188 | 0.88 | LMNA (0.51) | LMNACYP2C9KDM4ENPSR1MEN1 | |
| SCHEMBL9703752 | 0.81 | PKM (0.54) | LMNACYP2C9MEN1KMT2ATDP1 | |
| Sulfaquinoxaline SCHEMBL93789 | 0.81 | LMNA (1.00) | LMNACYP2C9SMN1; SMN2KDM4EMEN1 | |
| Sulfaquinoxaline SCHEMBL29391090 | 0.81 | LMNA (1.00) | LMNACYP2C9SMN1; SMN2KDM4EMEN1 | |
| Sulfaquinoxaline SCHEMBL4435622 | 0.81 | LMNA (1.00) | LMNACYP2C9SMN1; SMN2KDM4EMEN1 | |
| Sulfaquinoxaline SCHEMBL301314 | 0.80 | LMNA (0.97) | LMNACYP2C9SMN1; SMN2KDM4EMEN1 | |
| Sulfaquinoxaline SCHEMBL27961007 | 0.80 | LMNA (0.97) | LMNACYP2C9SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL9230544 | 0.79 | HTR2C (0.45) | LMNACYP2C9SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL9075934 | 0.78 | PIK3CD (0.45) | LMNACYP2C9SMN1; SMN2KDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101163468-A | Novel combination of sulfonamide compounds | EISAI R&D MAN CO LTD (JP) | 2008-04-16 | — | — | CN | claimed |
| EP-0215200-B1 | USE OF SULFANILAMIDO QUINOXALINES IN THE TREATMENT OF NEOPLASTIC DISEASES | MERCK & CO. INC. (US) | 1992-09-09 | — | — | EP | claimed |
| US-4931433-A | Method for treating certain neoplastic diseases | MERCK & CO., INC. (US) | 1990-06-05 | — | — | US | claimed |
| EP-0215200-A2 | Use of sulfanilamido quinoxalines in the treatment of neoplastic diseases | MERCK & CO. INC. (US) | 1987-03-25 | — | — | EP | claimed |
| EP-4694892-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TOPOISOMERASE INHIBITOR, A SPLICING INHIBITOR SULFONAMIDE, OR A KIF18 INHIBITOR | Ideaya Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024216145-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TOPOISOMERASE INHIBITOR, A SPLICING INHIBITOR SULFONAMIDE, OR A KIF18 INHIBITOR | IDEAYA BIOSCIENCES, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023215802-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215801-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| EP-1859793-A1 | NOVEL COMBINATIONAL USE OF SULFONAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-11-28 | — | — | EP | disclosed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-20050227929-A1 | Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent | PHARMACIA & UPJOHN, LLC | 2005-10-13 | — | — | US | disclosed |
| US-5529999-A | SULFONAMIDOQUINOXALINE DERIVATIVE | ELI LILLY AND COMPANY (US) | 1996-06-25 | — | — | US | disclosed |
| EP-0672662-A1 | Quinoxaline derivative used in the treatment of tumours | ELI LILLY AND COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| EP-0215200-B1 | USE OF SULFANILAMIDO QUINOXALINES IN THE TREATMENT OF NEOPLASTIC DISEASES | MERCK & CO. INC. (US) | 1992-09-09 | — | — | EP | disclosed |
| US-4931433-A | Method for treating certain neoplastic diseases | MERCK & CO., INC. (US) | 1990-06-05 | — | — | US | disclosed |
| EP-0215200-A2 | Use of sulfanilamido quinoxalines in the treatment of neoplastic diseases | MERCK & CO. INC. (US) | 1987-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | LMNA 2455/4885CYP2C9 4704/4885SMN1; SMN2 1539/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | LMNA 2568/4885CYP2C9 4269/4885SMN1; SMN2 1518/4885 |
| US-20050227929-A1 | Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent | PTGES2, PTGS2, PTGER2 | LMNA 2764/4885CYP2C9 1377/4885SMN1; SMN2 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.